Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

Cited In for PubMed (Select 21415352)

1.

Poorly Understood Aspects of Striated Muscle Contraction.

Månsson A, Rassier D, Tsiavaliaris G.

Biomed Res Int. 2015;2015:245154. Epub 2015 Apr 16. Review.

2.

Ensemble Force Changes that Result from Human Cardiac Myosin Mutations and a Small-Molecule Effector.

Aksel T, Choe Yu E, Sutton S, Ruppel KM, Spudich JA.

Cell Rep. 2015 May 12;11(6):910-20. doi: 10.1016/j.celrep.2015.04.006. Epub 2015 Apr 30.

3.

Myosin VI deafness mutation prevents the initiation of processive runs on actin.

Pylypenko O, Song L, Shima A, Yang Z, Houdusse AM, Sweeney HL.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1201-9. doi: 10.1073/pnas.1420989112. Epub 2015 Mar 6.

4.

Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs.

Teichman SL, Maisel AS, Storrow AB.

Crit Pathw Cardiol. 2015 Mar;14(1):12-24. doi: 10.1097/HPC.0000000000000031.

5.

The genetic landscape of cardiomyopathy and its role in heart failure.

McNally EM, Barefield DY, Puckelwartz MJ.

Cell Metab. 2015 Feb 3;21(2):174-82. doi: 10.1016/j.cmet.2015.01.013. Review.

PMID:
25651172
6.

Targets for therapy in sarcomeric cardiomyopathies.

Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, Maier LS, Ashrafian H, Huke S, van der Velden J.

Cardiovasc Res. 2015 Apr 1;105(4):457-70. doi: 10.1093/cvr/cvv023. Epub 2015 Jan 29.

PMID:
25634554
7.
8.

Animal and in silico models for the study of sarcomeric cardiomyopathies.

Duncker DJ, Bakkers J, Brundel BJ, Robbins J, Tardiff JC, Carrier L.

Cardiovasc Res. 2015 Apr 1;105(4):439-48. doi: 10.1093/cvr/cvv006. Epub 2015 Jan 18. Review.

PMID:
25600962
9.

Chaperone-enhanced purification of unconventional myosin 15, a molecular motor specialized for stereocilia protein trafficking.

Bird JE, Takagi Y, Billington N, Strub MP, Sellers JR, Friedman TB.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12390-5. doi: 10.1073/pnas.1409459111. Epub 2014 Aug 11.

10.

Analytical comparison of natural and pharmaceutical ventricular myosin activators.

Wang Y, Ajtai K, Burghardt TP.

Biochemistry. 2014 Aug 19;53(32):5298-306. doi: 10.1021/bi500730t. Epub 2014 Aug 7.

PMID:
25068717
11.

Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin.

Lindert S, Li MX, Sykes BD, McCammon JA.

Chem Biol Drug Des. 2015 Feb;85(2):99-106. doi: 10.1111/cbdd.12381. Epub 2014 Jul 11.

PMID:
24954187
12.

Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.

Nagy L, Pollesello P, Papp Z.

J Cardiovasc Pharmacol. 2014 Sep;64(3):199-208. doi: 10.1097/FJC.0000000000000113. Review.

13.

Cell-based delivery of dATP via gap junctions enhances cardiac contractility.

Lundy SD, Murphy SA, Dupras SK, Dai J, Murry CE, Laflamme MA, Regnier M.

J Mol Cell Cardiol. 2014 Jul;72:350-9. doi: 10.1016/j.yjmcc.2014.04.010. Epub 2014 Apr 26.

14.

Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.

Feest ER, Steven Korte F, Tu AY, Dai J, Razumova MV, Murry CE, Regnier M.

J Mol Cell Cardiol. 2014 Jul;72:219-27. doi: 10.1016/j.yjmcc.2014.03.015. Epub 2014 Mar 29.

15.

Hypertrophic cardiomyopathy: The need for randomized trials.

Olivotto I, Tomberli B, Spoladore R, Mugelli A, Cecchi F, Camici PG.

Glob Cardiol Sci Pract. 2013 Nov 1;2013(3):243-8. doi: 10.5339/gcsp.2013.31. eCollection 2013. Review.

17.

Sarcomere length nanometry in rat neonatal cardiomyocytes expressed with α-actinin-AcGFP in Z discs.

Shintani SA, Oyama K, Kobirumaki-Shimozawa F, Ohki T, Ishiwata S, Fukuda N.

J Gen Physiol. 2014 Apr;143(4):513-24. doi: 10.1085/jgp.201311118. Epub 2014 Mar 17.

18.

Small molecule-mediated refolding and activation of myosin motor function.

Radke MB, Taft MH, Stapel B, Hilfiker-Kleiner D, Preller M, Manstein DJ.

Elife. 2014 Feb 11;3:e01603. doi: 10.7554/eLife.01603.

19.

Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Poggesi C, Ho CY.

J Muscle Res Cell Motil. 2014 Feb;35(1):37-45. doi: 10.1007/s10974-014-9374-0. Epub 2014 Feb 4. Review.

20.

Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.

Botham RC, Fan TM, Im I, Borst LB, Dirikolu L, Hergenrother PJ.

J Am Chem Soc. 2014 Jan 29;136(4):1312-9. doi: 10.1021/ja4124303. Epub 2014 Jan 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk